Jim Simons
NRIX icon

Jim Simons’s Nurix Therapeutics NRIX Stock Holding History

Jim Simons’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Buy
+118,000
New +$1.96M ﹤0.01% 1951
2025
Q4 		– Sell
-184,800
Closed -$1.71M – 3586
2025
Q3 		$1.71M Buy
184,800
+162,900
+744% +$1.69M ﹤0.01% 2174
2025
Q2 		$249K Sell
21,900
-37,600
-63% -$406K ﹤0.01% 3095
2025
Q1 		$707K Buy
+59,500
New +$995K ﹤0.01% 2595
2024
Q4 		– Sell
-246,400
Closed -$5.54M – 3792
2024
Q3 		$5.54M Sell
246,400
-77,600
-24% -$1.76M 0.01% 1383
2024
Q2 		$6.76M Buy
324,000
+144,700
+81% +$2.25M 0.01% 1127
2024
Q1 		$2.64M Buy
179,300
+64,100
+56% +$689K ﹤0.01% 1837
2023
Q4 		$1.19M Buy
115,200
+88,400
+330% +$606K ﹤0.01% 2291
2023
Q3 		$211K Buy
+26,800
New +$245K ﹤0.01% 3074
2023
Q2 		– Sell
-28,900
Closed -$257K – 4160
2023
Q1 		$257K Sell
28,900
-89,800
-76% -$936K ﹤0.01% 3176
2022
Q4 		$1.3M Buy
118,700
+45,400
+62% +$548K ﹤0.01% 2372
2022
Q3 		$955K Sell
73,300
-45,100
-38% -$714K ﹤0.01% 2526
2022
Q2 		$1.5M Buy
118,400
+42,200
+55% +$478K ﹤0.01% 2410
2022
Q1 		$1.07M Buy
+76,200
New +$1.35M ﹤0.01% 2684

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Jim Simons's NRIX Position: Q1 2026 in Review

Jim Simons opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 118,000 shares worth $1.83M. The stake represents ﹤0.01% of the portfolio and ranks #1951 among its holdings. This is a return to the name: Jim Simons previously reported a position in NRIX as recently as Q3 2025.

Jim Simons first reported a position in NRIX in Q1 2022 and has held it in 14 quarters since. The position peaked at $6.76M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Jim Simons held 118,000 shares of Nurix Therapeutics worth $1.83M as of Q1 2026.
  • Nurix Therapeutics was a new Jim Simons position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #1951 holding.
  • Jim Simons first reported a position in Nurix Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Jim Simons's Nurix Therapeutics position peaked at $6.76M in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.